



FOR IMMEDIATE RELEASE

Jounce Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

Cambridge, Mass., July 11, 2016 – Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to a biomarker-driven patient enrichment strategy designed to match therapies to defined patient populations, today announced that Richard Murray, Ph.D., chief executive officer of Jounce Therapeutics, will present a company overview at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Wednesday, July 13, 2016 at 4 p.m. ET. The conference is being held July 12-13, 2016 at Le Parker Meridien Hotel New York City.

About Jounce Therapeutics

Jounce Therapeutics is an immuno-oncology company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights, including identification of related biomarkers, designed to match the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as knowledge acquired from Jounce's Translational Science Platform, to create a sustainable "discovery to human proof-of-concept" product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.

Media Contact:

Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com

###